A divergent asymmetric approach to aza-spiropyran derivative and (1S,8aR)-1-hydroxyindolizidine

• Jian-Feng Zheng,
• Wen Chen,
• Su-Yu Huang,
• Jian-Liang Ye and
• Pei-Qiang Huang

Beilstein J. Org. Chem. 2007, 3, No. 41, doi:10.1186/1860-5397-3-41

• drug for the treatment of cancer.[15] In addition, these molecules serve as platforms for testing synthetic strategies, and several asymmetric syntheses of both enantiomers of 1-hydroxyindolizidine (3) have been reported. [27][28][29][30][31][32][33][34]In continuation of our efforts in the development